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REFLECTIONS OF THE PIONEERSThe first successful combined heart–lung transplantationBruce A. Reitz, MDEveryone in the room was immediately captivated by the
sight of the large and empty thoracic cavity after the com-
plete heart–lung block had been removed from our recipi-
ent. It was March 9, 1981, and Drs Norman Shumway,
John Wallwork, and I were in the midst of an operation
that would result in a remarkable recovery for 45-year-old
Mary Gohlke, who was in the end stages of primary pulmo-
nary hypertension (PPH). The events that led up to this op-
eration, as well as Mary’s recovery and rehabilitation, are
the subject of this brief personal reflection, invited by Jour-
nal Editor, Dr Lawrence Cohn.
Twelve years earlier, I had arrived in Dr Shumway’s
Stanford department as a senior medical student seeking
a 6-month experience in the experimental laboratory. My
timing was good. It was early June 1969, and the Stanford
heart transplant program was well underway, directed by
Drs Shumway and Edward Stinson, who together had per-
formed the first adult human heart transplantation in the
United States in January of 1968. There was, of course,
a lot of excitement about heart transplantation in those
years, and I was privileged to observe the 14th Stanford
heart transplant and, more important, to work with Drs
Stinson and Eugene Dong in the experimental laboratory
of the department. Dr Shumway had always believed that
new procedures and techniques that were going to be intro-
duced in the operating room and in the care of patients
should first be studied as well as possible in the experimen-
tal laboratory. Being able to assist Ed Stinson in the exper-
imental laboratory as he performed heart transplants in
dogs was an enormous privilege and showed me the way
in which an extremely gifted surgeon went about perform-
ing meticulous and beautifully efficient operative proce-
dures. There was no question after that experience that I
wanted to be a cardiac surgeon. Two years later, I was
able to return to Dr Shumway’s team as a junior resident.
This was a unique training philosophy whereby residents
were introduced to cardiac surgery early after medical
school, somewhat like the integrated cardiac surgery train-
ing programs of today.
As I finished the chief resident year in 1976 and subse-
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The Journal of Thoracic and Catraining for Board certification, I was able to return to
the experimental laboratory part-time to work on the heart
transplant projects currently underway. In a casual conver-
sation, I asked Dr Shumway what needed to be done, and
he said that he would like to see some progress in the pos-
sibility of combining heart transplantation with complete
bilateral lung transplantation, inasmuch as there were pa-
tients with congenital heart defects and also patients with
severe lung disease who currently were not able to be
treated by transplantation. This led to some early heart–
lung transplants in dogs with Bill Baumgartner, MD.
Technically successful, it turned out to be an unsatisfac-
tory model, inasmuch as the respiratory pattern in dogs
was severely altered after denervation. Then, as a young
assistant professor in the department, I started to study
heart–lung transplants in small rhesus and cynomolgus
monkeys. These experiments were done with Nelson Bur-
ton, MD, and John Pennock, MD. In a short period of
time, we had developed a reliable method for performing
the heart–lung transplant in the small monkeys and
achieved survivors with both autotransplantation and allo-
transplantation, although we did not use immunosuppres-
sion. Nevertheless, Dr Shumway was quite excited by the
appearance of the monkeys, which were able to breathe
normally and were normally active after complete heart–
lung transplants. It was fun for us when he would include
the laboratory in his early morning rounds to check up on
their progress.
Fortuitously, another significant event for the field of
transplantation was developing in Europe at the time. A
new immunosuppressive compound known as cyclosporin
A had been identified in the laboratories of Dr Jean Borel
and his colleagues at Sandoz Inc. This compound, after ex-
perimental and then clinical work by Professor Roy Calne
and David White at Cambridge University, seemed to pro-
vide amazingly improved immunosuppression. In the sum-
mer of 1978, several months after the initiation of the
clinical trial of cyclosporin A in patients undergoing renal
transplants, David White visited Stanford and gave a semi-
nar to a small group of the heart transplant team. From that
meeting, Sandoz was contacted and agreed to provide the
Stanford laboratory with enough of the precious powder
for use both in rat heterotopic cardiac transplants and for
the primate experiments of heart and heart–lung transplan-
tation. At that time, the powder was dissolved in olive oil
and given as an intramuscular injection. Little was known
about the clinical use of the material, but it soon became ap-
parent when administered to the monkeys that the immuno-
suppression was superior to that of previous drug therapies.rdiovascular Surgery c Volume 141, Number 4 867
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anastomosis, and quick recovery of the animals to appar-
ently normal pulmonary and heart function.
The results of the heart–lung transplant experiments
were presented at the 60th Annual Meeting of The Amer-
ican Association for Thoracic Surgery in San Francisco in
April of 1980. This presentation turned out to be impor-
tant for two reasons. First, Drs Shumway, Stinson, and I
believed that the growing experience of long-term sur-
vival with the primates provided the basis for a clinical
trial. By early fall of 1980, we began to think about po-
tential patients. At the same time, the use of cyclosporine
for the regular heart transplant patients was being orga-
nized, and the Food and Drug Administration (FDA)
and the Stanford Institutional Review Board gave ap-
proval for that trial. The first heart transplant recipient
to receive cyclosporine was operated on in December of
1980. He and subsequent patients continued to show im-
proved postoperative recoveries that were clearly different
from those of the previous patients receiving steroids and
azathioprine.
Second, there were a few small newspaper accounts of
the presentation from The American Association for Tho-
racic Surgery, describing the monkeys that had survived af-
ter heart and lung replacement. One of these articles
appeared in the Mesa Tribune, in Mesa, Arizona, where
the advertising accounts manager, Mary Gohlke, happened
to see this article and immediately began to wonder whether
it might help her. Over the previous several years, she had
experienced a steady decline in her health and had been di-
agnosed with PPH. She had recently had to stop work and
was now extremely limited. She had gone to Houston to
consult with Dr Michael DeBakey, who confirmed her car-
diologist’s diagnosis and the information that there were no
effective treatments for the disease. Someone on the Hous-
ton team had mentioned to Mary that perhaps the only treat-
ment one could think about was to transplant the heart and
lungs, but ‘‘that was impossible.’’
Mary’s health was declining rapidly, she had two young
teenage sons, and she was intrigued enough by the newspa-
per clipping that she picked up the telephone and called the
Stanford Medical Center in the summer of 1980 and asked
to speak to me. I told her what we had learned and that it was
extremely experimental, but perhaps in the future, it might
be able to help her. Several months later, she called again to
say that her condition had worsened, and she wanted to
know whether there was any chance that we might consider
her for a transplant. So, in October, we arranged for Mary
and her husband to come up to Stanford to meet with me
and other members of the heart transplant team. After that
meeting, we knew she would be an excellent candidate.
Still, the heart transplant trial with cyclosporine had not
yet been started and other administrative procedures needed
to be resolved.868 The Journal of Thoracic and Cardiovascular SurgIn our discussion about potential candidates, patients
with PPH and Eisenmenger syndrome, particularly those
without previous cardiac surgery, were thought to be ideal
potential recipients. In PPH, the right heart, right atrium,
right ventricle, and pulmonary artery would be severely di-
lated and failing, and there would be a minimum of bron-
chial collaterals and potential adhesions. By the end of
the year, we were beginning to believe that cyclosporine
was indeed going to be a useful immunosuppressive strat-
egy. The Institutional Review Board at Stanford gave us ap-
proval for an initial patient. However, the FDA had not
approved the use of the drug for this indication, and this
was the major stumbling block before going ahead with
the procedure.
Early in 1981, Mary was becoming desperate about her
condition. When she heard that we were awaiting FDA ap-
proval, she called the editor of her newspaper, who had con-
tacts within the Arizona congressional offices. Through the
intervention of an Arizona senator, we soon received a pos-
itive response from the FDA. After this happened, Mary
moved from Arizona to Palo Alto to be near the center until
a suitable donor was identified. Inasmuch as lung preserva-
tion remained an unresolved question, we would again need
to transport donors to the center at the time of the operation
and harvest organs in the adjoining operating room. Mary
waited about 6 weeks until an excellent potential donor
was identified in Southern California, and arrangements
were made to transport to Stanford.
Needless to say, there was both excitement and anxiety as
we made preparations for something that we had been
working on in the laboratory over the past 5 years. John
Wallwork was the transplant fellow at that time, and he
and I worked hand-in-hand throughout the arrangements,
the operation, and the postoperative care of Mary and of
subsequent patients.
As is often customary, the actual transplant operation be-
gan shortly after midnight of March 9, 1981, and proceeded
exactly as we had learned the operation in many laboratory
procedures. We were used to excising the heart and both
lungs en bloc in the small monkeys, and this was done in
this operation as well. Subsequently, we would remove
the heart and then both lungs sequentially. Although this
added a little bit of extra time, the lack of adhesions and
the lack of troublesome bronchial collaterals facilitated
the operation. The right atrium, right ventricle, and pulmo-
nary artery were massively enlarged, and the specimen was
quite dramatic, with a very tiny left ventricle attached at the
septum to a huge right ventricular cavity. Mary had indeed
been struggling, and our timing of the operation was very
fortunate. As in the laboratory, we preferred the use of
a polypropylene suture for all anastomoses, including the
trachea, without any special wrapping of the anastomosis.
We had become convinced of the utility of the coronary-
to-bronchial collaterals that we had identified in theery c April 2011
FIGURE 1. Stanford team at the first successful heart–lung transplant,
March 9, 1981. At the operating table are Drs Shumway, Reitz, and Wall-
work. Observing (from left to right) are Drs Athanasuleas, Jamieson,
Baumgartner, and Giritsky.
Reitz Reflections of the Pioneersmonkeys. This and the improved immunosuppression we
believed would allow excellent healing. The donor organs
had been harvested in an adjoining operating room by Drs
Stinson and Philip Oyer. As shown in Figure 1, the operative
team consisted of Dr Shumway, John Wallwork, and me
with the Stanford residents and fellows, Connie Athanasu-
leas, Stuart Jamieson, Bill Baumgartner, and Alexander
Giritsky, looking on. The appearance of the totally empty
thorax was indeed a dramatic moment. I wondered whether
this was really going to work out. The implantation went
smoothly, the heart resuscitated quickly, and lung function
was adequate immediately. We returned to the Cardiac Sur-
gery Intensive Care Unit a little before 6:00 AM. The next
few weeks were a blur of activity, and a lot of it was directed
toward improving nutrition and physical therapy for reha-
bilitation. We relied on the use of transvenous endomyocar-
dial biopsy for the diagnosis of cardiac rejection, thinking
that this would be our major tool for the assessment of rejec-
tion of the total graft. Although we identified two rejection
episodes and treated them with pulses of methylpredniso-
lone (Solu-Medrol), it would only be several years later
that it was clearly determined that asynchronous heart and
lung rejection was more common and that it was more im-
portant to follow the pulmonary biopsy by means of serial
bronchoscopy.
Finally, Mary made a steady improvement and was dis-
charged from the hospital after 82 days. She remained in
the local area until 6 months postoperatively, when she re-
turned to her home in Mesa, Arizona, and eventually back
to work at the Mesa Tribune.
The next patient was 30-year-old Chuck Walker from
Binghamton, New York, who had Eisenmenger syndrome
owing to an unrepaired largemembranous ventricular septal
defect; he also underwent successful heart–lung transplan-
tation onMay 1, 1981. Both he andMary Gohlke were won-
derful ambassadors for the potential for total lung and heart
replacement and the field of transplantation in general.
Mary lived for a little over 5 years, when, unfortunately,
she died as a result of complications suffered after an acci-
dental fall. She did not have any findings of chronic rejec-
tion in either her lungs or heart at the time of death. HerThe Journal of Thoracic and Caspirit, courage, determination, and ultimately her willing-
ness to explore the unknown in the face of many previous
failures in human lung transplantation as a recipient of
a combined heart–lung transplant, made possible the era
of therapeutic lung transplantation.rdiovascular Surgery c Volume 141, Number 4 869
